| Literature DB >> 11394741 |
P Furet1, T Meyer, P Mittl, H Fretz.
Abstract
We have selected cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, as a target in our efforts to discover new antitumor agents. By exploiting available structural information, we designed an ATP-site directed ligand scaffold that allowed us to identify 4-(3-methyl-1,4-dioxo-1,4-dihydro-naphthalen-2-ylamino)-benzenesulfonamide as a new potent inhibitor of CDK1 in a subsequent database search. The synthesis and testing of some analogues confirmed the interest of this class of compounds as novel CDK1 inhibitors.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11394741 DOI: 10.1023/a:1011128510728
Source DB: PubMed Journal: J Comput Aided Mol Des ISSN: 0920-654X Impact factor: 3.686